Acronym
MoST 14 (substudy 32)
Project Title
A Single arm, open label, phase II trial of alectinib in patients with advanced tumours harbouring ALK gene alterations detected by comprehensive genomic profiling
Principal Investigator
Start Date
December 11, 2019
Keywords
ALK gene alterations Non-small cell lung cancer
Project Type
Interventional/Clinical trials research
